Centrient Pharmaceuticals offers the following Marketing Authorisations for transfer with supply obligation.

If your Marketing Authorisation is not listed here, please get in touch with us licensing@centrient.com and our dedicated licensing and regulatory teams will be happy to assist you on the best strategy to secure new Marketing Authorisations for you.

Beta-lactam

| Molecule | Dosage form | Strength | Procedure | Country | Sunset Clause |
|-------------------------------|----------------------------|--|-----------------------|---------------------|----------------------------------|
| Amoxicillin | Powder for oral suspension | 250 mg / 5 ml | DCP (NL/H/3413) | Netherlands | Not applied in NL |
| Amoxicillin + Clavulanic acid | Film-coated tablet | 500 mg + 125 mg (4:1) 875 mg + 125 mg (7:1) | duplicate (NL/H/3171) | Netherlands | Not applied in NL |
| Amoxicillin + Clavulanic acid | Film-coated tablet | 500 mg + 125 mg (4:1) | DCP (NL/H/3171) | UK/Northern Ireland | UK/Northern Ireland: Aug-2025 |
| Amoxicillin + Clavulanic acid | Powder for oral suspension | 200 mg + 28.5 mg / 5 ml | National Procedure | Lithuania | LT: Aug-2024 |

Statins

| Molecule | Dosage form | Strength | Procedure | Country | Sunset Clause |
|--------------|--------------------|---|--------------------|---|---|
| Atorvastatin | Film-coated tablet | 10 mg 20 mg 30 mg 40 mg 60 mg 80 mg | DCP (NL/H/3794) | Netherlands, UK/ Northern Ireland, Ireland | UK/Northern Ireland: Jul-2023 IE: undefinitely NL: not applied |
| Atorvastatin | Film-coated tablet | 10 mg 20 mg 30 mg 40 mg 60 mg 80 mg | National Procedure | France | FR: Feb 2024 |
| Rosuvastatin | Film-coated tablet | 5 mg 10 mg 20 mg | DCP (DK/H/2621) | Denmark, France | DK: not applied FR: April 2023 |
| Rosuvastatin | Film-coated tablet | 5 mg 10 mg 20 mg 40 mg | DCP (DK/H/2651) | Denmark, Hungary, Poland | DK: not applied HU: April 2023 PL: Feb 2024 |



Centrient Pharmaceuticals offers the following Marketing Authorisations for transfer with supply obligation.

If your Marketing Authorisation is not listed here, please get in touch with us <u>licensing@centrient.com</u> and our dedicated licensing and regulatory teams will be happy to assist you on the best strategy to secure new Marketing Authorisations for you.

Anti-fungals

| Molecule | Dosage form | Strength | Procedure | Country | Sunset Clause |
|-------------|--|---------------|--------------------|--------------|------------------------------|
| Caspofungin | Powder concentrate for infusion solution | 50 mg 70 mg | DCP (MT/H/0217) | Malta, Italy | MT: Jan 2023 IT: Jan 2025 |
| Caspofungin | Powder concentrate for infusion solution | 50 mg 70 mg | National Procedure | France | FR: March 2023 |

